Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 1.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 30,833 shares of the medical research company’s stock after selling 335 shares during the period. Hancock Whitney Corp’s holdings in Edwards Lifesciences were worth $2,848,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth about $28,000. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at approximately $28,000. First Community Trust NA purchased a new stake in Edwards Lifesciences in the second quarter valued at approximately $29,000. Riverview Trust Co acquired a new position in Edwards Lifesciences during the first quarter worth $34,000. Finally, Pingora Partners LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth $38,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EW has been the topic of several research reports. UBS Group decreased their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Citigroup raised their price objective on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Stifel Nicolaus cut their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Finally, Baird R W lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Sixteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $79.82.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The disclosure for this sale can be found here. In the last three months, insiders sold 16,250 shares of company stock valued at $1,218,138. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.6 %

Shares of NYSE:EW opened at $66.83 on Friday. The firm has a 50 day simple moving average of $69.89 and a 200-day simple moving average of $82.83. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $40.27 billion, a PE ratio of 28.81, a P/E/G ratio of 2.85 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same period last year, the business earned $0.66 EPS. Edwards Lifesciences’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.7 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.